Wedbush Weighs in on Nuvalent’s Q1 Earnings (NASDAQ:NUVL)

Nuvalent, Inc. (NASDAQ:NUVL) – Investment analysts at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for shares of Nuvalent in a report issued on Monday, November 17th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($1.51) per share for the quarter. Wedbush currently has a “Outperform” rating and a $125.00 target price on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Wedbush also issued estimates for Nuvalent’s Q2 2026 earnings at ($1.58) EPS, Q3 2026 earnings at ($1.64) EPS and Q4 2026 earnings at ($1.69) EPS.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter in the previous year, the business earned ($1.28) earnings per share.

Other equities research analysts also recently issued reports about the stock. Guggenheim lifted their price target on shares of Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group boosted their target price on Nuvalent from $114.00 to $132.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a report on Wednesday, October 8th. Leerink Partners boosted their price objective on Nuvalent from $140.00 to $149.00 and gave the company an “outperform” rating in a report on Monday. Finally, Cantor Fitzgerald assumed coverage on Nuvalent in a report on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 target price on the stock. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Nuvalent has a consensus rating of “Moderate Buy” and a consensus target price of $137.69.

Nuvalent Stock Down 3.5%

Nuvalent stock opened at $104.24 on Wednesday. Nuvalent has a 12-month low of $55.53 and a 12-month high of $112.53. The firm’s fifty day moving average is $89.11 and its 200 day moving average is $81.25. The company has a market capitalization of $7.58 billion, a PE ratio of -19.59 and a beta of 1.31.

Institutional Investors Weigh In On Nuvalent

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its stake in Nuvalent by 588.5% in the 1st quarter. CWM LLC now owns 420 shares of the company’s stock valued at $30,000 after buying an additional 359 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Nuvalent in the first quarter valued at approximately $38,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Nuvalent during the third quarter valued at approximately $38,000. Eastern Bank bought a new stake in Nuvalent during the third quarter worth $52,000. Finally, Covestor Ltd boosted its position in Nuvalent by 705.7% in the first quarter. Covestor Ltd now owns 983 shares of the company’s stock worth $70,000 after purchasing an additional 861 shares during the last quarter. 97.26% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Nuvalent news, CEO James Richard Porter sold 27,000 shares of the firm’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $90.63, for a total transaction of $2,447,010.00. Following the transaction, the chief executive officer directly owned 249,062 shares in the company, valued at approximately $22,572,489.06. This trade represents a 9.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew Shair sold 32,455 shares of the company’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $100.27, for a total transaction of $3,254,262.85. Following the completion of the sale, the director owned 1,383,044 shares of the company’s stock, valued at approximately $138,677,821.88. The trade was a 2.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 246,071 shares of company stock valued at $22,589,016. 10.20% of the stock is currently owned by company insiders.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.